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Abstract 
This paper examines the botulinum toxin industry and is it profitable to enter. In 
particular, the paper aims to define whether the industry structure is attractive because an 
industry is considered profitable only if it has attractive structure. This has been explored 
through applying the Porter’s five forces framework which provides a good 
understanding of farces shaping the industry and thus help to define the industry 
structure. It has been shown that the BTX industry has been characterized by relatively 
strong rivalry, moderate threat of new entrance, threat of substitutes and the power of 
buyers and low power of supplies. This structure determines the industry as an attractive 
one and thus is assumed to be a profitable to enter.  
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Preface  
 
When choosing the topic for my thesis, my first criterion was to write about an issue that 
I am interested in. While reading everyday’s newspapers, I was amazed by the growing 
influence and power of the botulinum toxin industry in the cosmetic and medical use 
worldwide. Botulinum toxin is used in cosmetics to stop aging process and for this reason 
it became very popular, especially in more affluent societies. In order to learn more about 
the issue, I did a preliminary research of the market and found an interesting strategy case 
to be analyzed witch triggered my interest further.  
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more reason. This thesis aims to help a potential new entrant that is considering entering 
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entry and high growth markets could be evaluated and hence approached by new entrants.  
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Bergen, Norway 
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INTRODUCTION 
Botulinum toxin has become widely known and gained a lot of attention in the public, 
mostly in respect to its use in cosmetics. In cosmetic treatments it is used to correct 
wrinkles and frown lines. The desire to look beautiful and young among older age groups 
is increasing along with the public approval of cosmetic treatments rising the awareness 
and the demand  for the cosmetic botulinum toxin treatments. However, the toxin is less 
known for its multiple therapeutic uses where it has been used to help patients that suffer 
from strabismus, blephoraspasm, dystonia or other movement nerve-related disorders. Its 
therapeutic use also has been constantly increasing over the past couple of decades and it 
is assumed that new applications will continue to evolve. Overall, botulinum toxin market 
is assumed to grow in two digit percent.  
 
The most known botulinum toxin product is Botox® produced by Allergan. Being 
present for twenty years and having approximately 85% of the market, Botox® achieved 
such a strong positioning that the whole botulinum toxin industry is often labeled as 
botox. Except for Allergan, there are a several other market players present: Ipsen, Medy-
tox,  Merz Pharmaceuticals, Mentor corporation and Solstice Neuroscience. The rest of 
the market is split among them.  
 
Problem to be addressed 
Given the fact that the botulinum toxin industry is a high growth industry makes it an 
attractive opportunity to enter. However, the botulinum toxin market, as each 
pharmaceutical branch, is expected to have high entry barriers such as high R&D 
investments, high patent cost, long time of clinical testing and regulative approvals of the 
drug use. Thus, having in mind high entry barriers, attractive growth and one strong 
player dominating the market, a question arises:  
 
Botulinum toxin industry – is it a profitable industry to enter? 
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According to Porter, “an industry is profitable only if its structure is attractive”.1 
Therefore, the purpose of the paper will be to analyze the structure of the BTX industry. 
To define the structure of the industry the Porter’s five forces model will be used. Major 
reason for choosing particularly this model is that it helps in evaluating strength of 
competition in an industry by looking at five different forces. The model will aim to 
determine whether the forces are intense and how the five forces shape the botulinum 
toxin industry.   Therefore, the paper will also try to answer following questions: 
 What are the main threats to a new entrant? 
 Where do opportunities for a new entrant lie?  
My findings indicate that the industry has an attractive structure and hence should be 
profitable to enter.   
 
The structure of the paper 
The structure of the paper consists of five main chapters. The first chapter will discuss the 
methods used to obtain data. The second chapter will try to describe what botulinum 
toxin is and where and how it is used. The third chapter presents the theoretical 
background for the analysis conducted in the fourth chapter. Therefore, in order to 
evaluate whether the industry is attractive to enter, the Porter’s five forces framework 
will be applied. Thereafter, the qualitative analysis of the case will be done in the fourth 
chapter which is also the most important chapter. The fifth chapter will present the main 
conclusions drawn from the previous chapter and the recommendations for a new entrant.  
 
Figure 1. Structure of the thesis 
 
                                                 
1 Porter, M.E. (2008) The five competitive forces that shape strategy, Harvard Business Review, January, 
pg. 47  
Background 
information 
about BTX 
 
Theoretical  
framework 
 
       Analysis 
 
     Conclusion 
 8
1. METHODS USED TO OBTAIN DATA/RESEARCH 
DESIGN 
 
The purpose of this chapter is to give an overview of the research methods used to obtain 
data for this thesis. To answer the research questions of the thesis, a qualitative research 
will be conducted.  The qualitative research is suitable for this particular problem because 
“qualitative is a synonym for any data collection technique or data analysis procedure 
that generates or use non-numerical data”2.  The thesis will be built on the case study 
research strategy since “case study examines a phenomenon in its natural setting, 
employing multiple methods of data collection to gather information from one or a few 
entities (people, groups, or organizations.)”.3 The data collection method used will be a 
document analysis that will embrace different official and public publications (i.e. 
secondary data) and desk research. Desk research involves collecting (secondary) data 
that already exists either from internal sources, publications of governmental and non-
governmental institutions, free access data on the internet, in professional newspapers 
and magazines, in annual reports of companies and commercial databases.4 The findings 
will be analyzed through a model acquired from strategic management literature, the 
Porter’s five forces framework. 
 
Secondary data was collected through several sources. First, the background information 
was gathered through newspapers and articles. News sources include reputed publications 
like Reuters, and Medicalnewstoday.com. Second, companies’ annual reports, 10-K 
reports, press releases and web pages were used to obtain company- and product-specific 
information. The largest part of secondary data came from this source. The companies 
whose data was investigated include: Allergan, Ipsen, Medy-tox,  Merz Pharmaceuticals, 
Mentor corporation and Solstice Neuroscience.  Third, institutional publications or 
announcements such as those from FDA,  American society for Aesthetic Plastic Surgery 
                                                 
2 Saunders, M., Lewis, P., and Thornhill A., (2007). Research methods for business students, 4th edition, 
Pearson Education Limited, Harlow, UK, Financial Times Prentice Hall, pg. 139 
3 Benbast, I., Goldstein, D.K., Mead, M. (1987) The case research strategy in studies of information 
systems, MIS quaterly, Vol. 11, No 3 
4 Wikipedia, the free encyclopedia, http://en.wikipedia.org/wiki/Desk_research; 16.12.2009. 
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or Dystonia foundation were used to fill in the gaps with regards to the industry 
dynamics. Additionally, other sources, such as customer forums or social networking 
sites, were used in order to gather wider perspective of the topic and in order to provide 
the author with another perspective of discussed topic.  
 
In order to better illustrate elements influencing the Porter’s five forces of the BTX 
industry a subjective evaluation was used.  The evaluation was conducted based on the 
information obtained and on author’s personal knowledge and interpretation. A scale 
used in the evaluation was one to five (1-5). One was determined as the low influence, for 
example; since there are hardly any suppliers, their power is evaluated as one (1). On the 
other hand, a strong and affluent driver was rated as five (5). Furthermore, if a driver is 
strong but not heavily expressed, it was evaluated as four (4). For example, all 
manufacturers clearly emphasize their strong commitment to the industry and hence the 
element is ranked as five (5). Price competition although existing, is not so strong as 
competitors also focus to compete on other dimensions and  hence is ranked as four (4).   
 
Literature overview was built on the several academic publications. Strategic books such 
as Hitt, Ireland & Hokisson, Porter and Peng, were used and supplemented with strategic 
journal articles like Porter, Schofield and Markovitz. Research publication on pharmacy 
and botulinum toxin like Jankovic, Hamdy et al., Dressler & Saberi were also used to 
provide the author with more insight of the industry, surrounding challenges, and 
observations about particular cases.  
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2. PRESENTATION OF BOTULINUM TOXIN   
In order to provide a reader with better understanding of the BTX industry some main 
and basic information defining what botulinum toxin is, how and where is used and also 
how it works will be given in this section.  
 
Botulinum toxin (BT) is a fermentation product of the anaerobic spore-forming bacterium 
Clostridium botulinum.5  Botulinum toxin is a neurotoxin known as the most poisonous 
biological substance.6 There are seven stereotypes of botulinum neurotoxins: A,B,C1, 
D,E,F and G. 7 Although all of them inhibit acetylcholine release from nerve terminals, 
but they considerably differ in their intracellular target proteins, characteristics of action 
and potencies.8 For example, application of BTX-A has a duration of 4-6 month, while 
the BTX-F will create an effect that will last only for 3 weeks. 9  The toxin consists of a 
complex mixture of proteins containing botulinum neurotoxin and different non-toxin 
proteins. 10   
 
The toxin operates through binding to the nerve ending at the point where the nerve joins 
a muscle. It blocks the release of the chemical acetylcholine (the principal 
neurotransmitter at the neuromuscular junction) which is required for muscle contraction. 
The immediate result is weakness and paralysis of the muscle, while over time and the 
muscle atrophies. The blockage of acetylcholine release is irreversible. The function can 
                                                 
5 Hamdy R.C., Montpetit K., Ruck-Gibs J., Thorstad K., Raney E., Aiona M., Platt R., Finley A., 
Mackenzie W., McCarthy J., Narayanan U., (2007). Safety and efficacy of botox injection in alleviating 
post-operative pain and improving quality of life in lower extremity limb lengthening and deformity 
correction, Trials, 8:27, www.trialsjournal.com/content/8/1/27  
6 MedicineNet, Definition of botulinum toxin, 
http://www.medterms.com/script/main/art.asp?articlekey=25769; 25.08.2008 
7 Hamdy R.C., Montpetit K., Ruck-Gibs J., Thorstad K., Raney E., Aiona M., Platt R., Finley A., 
Mackenzie W., McCarthy J., Narayanan U., (2007). Safety and efficacy of botox injection in alleviating 
post-operative pain and improving quality of life in lower extremity limb lengthening and deformity 
correction, Trials, 8:27, www.trialsjournal.com/content/8/1/27  
8 Dressler,D., Saberi, F.A., (2005) Botulinum toxin: Mechanisms of Action, European Neurology;  53,1, 
ProQuest Medical Library  
9 Borodic G., Johnson, E., Goodnough, M., Schantz, E., (1996). Botulinum toxin therapy, immunologic 
resistance and problems with available materials. Neurology 46:26-29 
10 Dressler,D., Saberi, F.A., (2005) Botulinum toxin: Mechanisms of Action, European Neurology;  53,1, 
ProQuest Medical Library   
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be recovered by the development of nerve terminals and the formation of new synaptic 
contacts, which usually takes 2 to 3 months.11  
 
Botulinum toxin, although a poison,  it has been used in the medical and cosmetic use for 
more than two decades. For example, BTX-A has been used as a therapeutic agent since 
the late 70s and has under medical supervision shown to be a safe drug. Types A and B 
are the only serotypes used in clinical practice. 12 
The potential for the toxins therapeutic use was recognized as far back as in 1817 by 
Justin Kerner who recognized that the toxin paralyzed skeletal muscles and 
parasympathetic function. However, FDA first time approved BTX for its therapeutic use 
in 1989 which included the use of the toxin as a cure in strabismus, blephoraspasm, and 
other facial nerve disorders. Today, the toxin’s clinical applications embrace dystonia and 
related movement disorders, spasticity and other hypertonic disorders, muscle spasm and 
other painful disorder including headaches, disorders of autonomic nervous system, 
nystagmus, palatal myoclonus and stridor. 13 The use of BTX is expanding constantly as 
new therapeutic applications are being discovered.  
More interest in BTX is caused by its cosmetic and dermatological application.  The 
cosmetic use of BTX applies to the correction of wrinkles and frown lines. BTX is used 
to smooth frown and wrinkle lines of the forehead, glabella and lateral periorbital area. 
The paralysis of the area under treatment should usually last approximately 4-6 months, 
eliminating completely the frown and wrinkle lines. Since the botulinum toxin spreads 
easily, the BTX cosmetic treatment actually aims only at weakening the muscle and not  
total paralysis. 14  
The adverse effects of using the botulinum toxin can be divided in short and long term 
complications. Diffusion of the toxin, causing an undesirable spread away from the 
                                                 
11 MedicineNet, Definition of botulinum toxin, 
http://www.medterms.com/script/main/art.asp?articlekey=25769; 25.08.2008 
12 Hamdy R.C., Montpetit K., Ruck-Gibs J., Thorstad K., Raney E., Aiona M., Platt R., Finley A., 
Mackenzie W., McCarthy J., Narayanan U., (2007). Safety and efficacy of botox injection in alleviating 
post-operative pain and improving quality of life in lower extremity limb lengthening and deformity 
correction, Trials, 8:27, www.trialsjournal.com/content/8/1/27  
13 Jankovic, J. (2004) Botulinum toxin in clinical practice, Journal of Neurology, Neurosurgery & 
Psychiatry 2004, 74: 951-957. Downloaded from jnnp.bmj.com on Nov 13th 2009  
14 Benedetto, A.V., (1999) The cosmetic uses of botulinum toxin type A, International journal of 
dermatology, 38, 641-655 
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injection point is considered a short term complication. Immunologic resistance is a 
major long term complication. 15 The immunologic resistance to BTX occurs after 
repeated use (medical and cosmetic treatments) and/or where patients received high doses 
(which is usually the case in medical treatments). The resistance to the BTX therapy is 
related to the development of neutralizing antibodies. Klein states that the incidence of 
clinical resistance to the BTX treatment in the cervical dystonia has been approximated to 
6,5%. Other complications connected to the use of the BTXs are also ptosis, tearing, 
vertical deviations and dry eyes. 16 Adverse effects of use of BTX are more serious 
among medical use than in the cosmetic treatments. This was  also confirmed by Cote et 
al. whose study showed that in the period December 2001 to November 2002, the 
proportion of reports classified as serious was 33-fold higher for therapeutic than for 
cosmetic cases.17 Cote et al. concluded in their study that this may be related to higher 
doses, complicated underlying diseases, or both. 18 
 
Figure 2. Before and after the BTX cosmetic treatment.  
 
 
Source: http://www.baltimore-eyecare.com/the-expert-opinion/uploaded_images/botox_ba_l-755060.gif ; 
16.12.2009. 
                                                 
15 Borodic G., Johnson, E., Goodnough, M., Schantz, E., (1996). Botulinum toxin therapy, immunologic 
resistance and problems with available materials. Neurology 46:26-29 
16 Klein, A.W., (2001) Complications and adverse reactions with the use of botulinum toxin, Seminars in 
cutaneous medicine and surgery, vol 20, No 2: pp 109-120 
17 The 217 serious adverse events (AE) reported in therapeutic cases involved a wide spectrum of events 
and included all 28 reported deaths. Among cosmetic users, no deaths were reported and, of the 36 serious 
AEs, 30 were included as possible complications in the FDA-approved label. 
18 Coté, T.R., Mohan A.K., Polder J.A., Walton M.K., Braun M.M. (2005) Botulinum toxin type A 
injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic 
cases. Journal of American Academy of Dermatology.  Sep;53(3):407-15  
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3. PORTER'S FIVE FORCES - THEORETICAL 
FRAMEWORK 
One of the most accepted theories on competition and strategy is Porter's five forces 
analysis. This analysis became widely accepted because it broadens the “old” competition 
concept. Usually the competition analysis embraces the companies that offer a 
competitive product or service. However, Porter conjoined four additional forces (threat 
of new entrants,  threat of substitutes, bargaining power of buyers, and bargaining power 
of suppliers) to the rivalry among existing competitors, stating that all five of them 
together determine an industry’s attractiveness and competitive position. 19 The stronger 
the forces are, the more difficult it is to earn returns on investment, making the industry  
less attractive to new entrants (and vice versa).20   
Figure 3. The Porter’s five forces framework 
  
                                                 
19 Porter, Michael E. (2008) On Competition, Updated and expanded Edition, A Harvard Business Review 
Book  
20 Porter, M.E. (2008) The five competitive forces that shape strategy, Harvard Business Review, January 
The threat of 
new entrants 
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of buyers 
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The threat of new entrants 
The threat of a new entrant in an industry is relevant  since an entrant seeks to capture 
market share. 21   Porter determined the threat of a new entrant by the entry barriers and 
by the incumbents’ reaction to the entry. Entry barriers include: economies of scale, 
product differentiation that is related to customer loyalty, capital requirements, switching 
costs, access to distribution channels, cost disadvantage independent of scale and 
government policy. 22 When producing on a large scale, the unit costs decline. This can  
apply not only to the  production but also to the R&D, marketing and other value chain 
activities.  Entering a new industry requires resources not only to finance new facilities, 
inventories, marketing, R&D and other business activities, but also to gain the access to  
the distribution channels that existing competitors already have developed. 23 Knowledge, 
expertise and patent ownership are also forms of entry barriers. Long experience in an 
industry and knowledge accumulated over the years may pose a high entry barrier, as it 
can be very difficult for an entrant to copy and gain the necessary experience in a short 
time.24 High switching cost will discourage a new entrant. Switching costs are costs that 
customers bear when they purchase from another producer and in some cases they may 
be time dependant i.e. lower at the beginning of the customer lifecycle and rising towards 
the later stages of the cycle. On the other hand, retaliation from incumbents may 
additionally prevent new entrants. Vigorous retaliation can be expected from a company 
that holds a great stake of a market25 but also if the incumbent has resources to fight back 
and has previously responded vigorously to the newcomers. 26 However, finding a market 
niche that is not covered by incumbents may be an opportunity for a new entrant. Hitt et 
                                                 
21 Porter, M.E. (2008) The five competitive forces that shape strategy, Harvard Business Review, January 
22 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation 
23 Porter, Michael E. (2008) On Competition, Updated and expanded Edition, A Harvard Business Review 
Book  
24 Peng, M.W. (2006) Global Strategy, International student edition, South-Western, Thomson Corporation 
25 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation 
26 Porter, Michael E. (2008) On Competition, Updated and expanded Edition, A Harvard Business Review 
Book  
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al. state that small entrepreneurial firms are usually very skilled at finding these 
opportunities. 27  
 
Low entry barriers and low retaliation  combined with high profit margins will attract 
new entrants. It is observed that where the threat is high, incumbents should keep the 
prices down or encourage investment to inhibit potential competitors from entering the 
industry. 28  Porter claims that it is the threat of an entry not whether the entry actually 
occurs, that holds down the profitability.  
Bargaining power of suppliers 
Suppliers support a company with the labor, raw materials, equipment, transportation and 
financial services. These costs influence the company’s profitability. If the suppliers are 
powerful they will charge high prices for their services and hence press profitability out 
of an industry. A supplier group can embrace power in several ways. Their power is high 
if the industry is dominated by a few large companies and is more concentrated than the 
industry to which it sells. Satisfactory substitute products not available to industry firms 
increase suppliers’ power too. 29 Another example is, according to Porter, when  firms are 
not important customers of the supplier group or when suppliers’ goods are critical to 
buyers’ success. Porter lists high switching costs of suppliers and highly differentiated 
services or products offered by the supplier as additional factors that nourish suppliers’ 
power. 30 Contrary, if the bargaining power of suppliers is weak; the company then has 
more power and therefore may negotiate favorable terms for itself. 31 
In pharmaceutical industry supplier power is also enhanced by strict governmental 
regulations these suppliers must fulfill in order to be accredited to supply. For example, 
                                                 
27 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation 
28 Porter, Michael E. (2008) On Competition, Updated and expanded Edition, A Harvard Business Review 
Book  
29 Porter, Michael E. (2008) On Competition, Updated and expanded Edition, A Harvard Business Review 
Book  
30 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation 
31 Peng, M.W. (2006) Global Strategy, International student edition, South-Western, Thomson Corporation 
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in USA the subcontractor is required by FDA to fulfill a variety of legislation.32 
Subcontracting the research and manufacturing activities is especially the case and plays 
common practice an important role for small and emerging pharmaceutical companies.33 
These do not have developed their own facilities and hence the subcontractors owe a 
great share of power.  
The power of buyers 
Buyers are the customers of the industry. They are considered powerful if they have 
negotiating leverage relative to the producers and/or if they are price sensitive.  
Negotiation leverage is achieved, claims Porter, if there are few buyers, the products 
offered by industry are standardized, switching among producers bears low costs for 
customers and if there are possibilities for customers to integrate backward. 34 In addition, 
customers today are more complex in their demands and are not solely lead by 
purchasing costs.35 They evaluate dimensions of quality and the total service/product 
package. Furthermore, introduction of Internet provided customers with an easier way of 
obtaining information on products and manufacturers’ cost and use it as distribution 
alternative. This significantly increased buyers’ bargaining power in many industries. 
This phenomenon can be explained by zero switching costs for customers when they 
decide to purchase from one manufacturer rather than another or from one dealer as 
opposed to a second or third one. 36  
Buyers’ price sensitivity is strengthened if product costs hold significant share of the 
customer’s budget, customers earn low profits, if the quality of buyers’ products or 
services is little affected by the industry’s product and if the industry’s product has little 
effect on the buyer’s other costs. 37      
                                                 
32 Allergan 10-K report 2007 
33 Van Arnum, P., (2008) Outsourcing strategies of emerging pharma, Pharmaceutical Technology;  32, 10; 
ABI/INFORM Global 
34 Porter, M.E. (2008) The five competitive forces that shape strategy, Harvard Business Review, January  
35 Schofield, R.A., Breen, L., (2006) Suppliers do you know your customers? International journal of 
quality and reliability management, Vol. 23, No 4,   
36 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation 
37 Porter, M.E. (2008) The five competitive forces that shape strategy, Harvard Business Review, January  
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Porter also emphasizes the role of intermediate customers as they can gain significant 
bargaining power if they can influence the purchasing decision of end customers. 38   
These new circumstances are forcing many industries to reconsider their strategies.  
Threat of substitute products 
A substitute is a product that performs the same or similar function as an industry product 
but does so in a different way or by different tools. 39  A substitute will pose a threat if its 
quality and function are superior to existing products and if they bear low switching 
costs. 40 Thus, “differentiating a product along dimensions that customers value (like 
product features, support services, delivery time, etc…) reduces a substitute’s 
attractiveness”. 41 In pharmaceutical industry, switching from a branded medicine to a 
generic one is caused by low costs and hence the shift to generics is substantial and rapid. 
In addition, producers should keep their eyes open in the direction of new technologies 
and other “out of the focal industry” environment since substitutes may originate from 
areas that are not directly related to the focal industry. 42  
Rivalry among existing competitors 
All firms within an industry are mutually dependent. Actions taken by one firm motivate 
reaction from its competitors. In other words, firms actively compete against one another. 
Competitive rivalry is fueled by competitor’s actions or when a company pursues 
opportunities to improve its market position. 43 Intense rivalry is witnessed by price wars, 
high rates of innovation and expensive marketing. 44  
                                                 
38 ibidum 
39 ibidum 
40 Peng, M.W. (2006) Global Strategy, International student edition, South-Western, Thomson Corporation 
41 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation, pg. 57 
42 Porter, M.E. (2008) The five competitive forces that shape strategy, Harvard Business Review, January  
43 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation 
44 Peng, M.W. (2006) Global Strategy, International student edition, South-Western, Thomson Corporation 
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Porter counted following factors that increase the intensity of rivalry: numerous 
competitors, slow industry growth, high exit barriers, strong commitment to the business 
by rivals and lack of literacy of rivals’ signals. Furthermore, rivalry pressures profitability 
if there is a price competition. The price competition is fueled, states Porter, by similarity 
and low switching costs of competitive products, high fixed and low marginal costs and 
by product perishability. However, competition on dimensions other than price (for 
example on product features, customer service, delivery time, brand), elaborates Porter, is 
less likely to diminish profitability because it actually increases customer’s value and can 
lead to higher prices instead. 45   
Conclusion  
The model of the five forces presents five competitive forces that in Porter’s view define 
the industry structure. The stronger are the forces, the lower is the profit potential of the 
industry. 46 Hence, the industry structure is an important factor in determining the 
industry’s long-run profit potential and attractiveness.47 According to Porter, an 
unattractive industry will have structural flaws, plethora of substitutes, powerful and 
price-sensitive buyers, strong rivalry and large competitors. On the other hand, an 
industry is attractive not only because of  having a high average return on investment, but 
also since it is difficult to enter (due to the high entry barriers), suppliers and buyers have 
only modest bargaining power, substitutes are few and rivalry among competitors is 
stable.48  
Below is a summary-table (Table 1.) presenting most of the factors including in which 
direction (high, low) their effect strengthens each of the force.   
 
 
 
                                                 
45 Porter, M.E. (2008) The five competitive forces that shape strategy, Harvard Business Review, January  
46 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation 
47 Porter, M.E. (2008) The five competitive forces that shape strategy, Harvard Business Review, January  
48 Porter, M., E., (1987). From competitive advantage to corporate strategy, Harvard Business Review, 
May-June 
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Table 1. Forces and their factors increasing the competitive structure of an industry 
Forces and their relating factors 
Impacts of the 
factors. 
It increases the 
force/threat/power 
if the factor is: The threat of new entrants 
Entry barriers low 
Economies of scale high 
Product differentiation low 
Capital requirements low 
Switching costs low 
Access to  distribution channels easy 
Market growth high 
Government policy low 
Incumbents' reaction to the new entry high 
A number of companies that hold great stake of the 
market low 
Bargaining power of suppliers   
Dominance of suppliers in the industry high 
Concentration of suppliers high 
Criticalness of suppliers' goods to the industry buyers high 
Importance of buyers as a customers to suppliers low 
Switching cost of suppliers high 
Suppliers' services' or products' differentiation high 
The power of buyers   
Negotiation leverage: HIGH 
Numerousness of buyers low 
Standardized products yes 
Switching costs low 
Product integration backward 
Customer's demands high 
Price sensitivity HIGH 
A share products hold of the customers' budget high 
Customers' income low 
The power of intermediate customers HIGH 
Threat of substitutes:   
Quality and function of a substitute high 
Switching costs low 
Rivalry among existing competitors:   
Numerousness of competitors high 
Industry growth low 
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Exit barriers high 
Commitment to the industry business high 
Price competition: high 
Switching costs low 
Product differentiation low 
Fixed costs high 
Marginal costs low 
Product perishability high 
Competition on other dimensions low 
 
Porter’s five forces framework is considered a static framework because it describes an 
industry as a constant and externally defined. This can be observed as a limitation. The 
model assumes that the competition is driven by the industry structure and that 
companies are constrained by it. In reality, however, competition is a dynamic process 
and firms continuously influence and alter the industry structure through delivering new 
technologies, substitute products and distribution channels or engagement in collusive 
behavior. 49 
 
                                                 
49 Sudarsanam S. (2003). Creating value from merger and acquisitions- the challenges, Prentice Hall-
Financial Times  
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4. PORTER'S FIVE FORCES ANALYSIS APPLIED TO BTX 
INDUSTRY 
 
In this chapter the Porter’s five forces analysis will be applied to the industry of 
botulinum toxin. Botulinum toxin production is perceived as an industry since “an 
industry is considered a group of firms that are close substitutes”. 50 Botulinum toxin 
manufacturers compete for the use of toxin in the same or very similar medical and 
cosmetic treatments.  
 
The chapter will aim to define elements that build Porters five forces in the BTX 
industry. Furthermore, the chapter will try to define in which direction and why these 
elements influence particular force. The final evaluation, the conclusion and 
recommendation part, will be built upon the findings from this chapter.  
 
The industry analysis will be performed on the global market because BTX is a global 
phenomenon. In addition, the competitive analysis will be narrowed to the business unit 
levels where needed, as the manufacturers’ activities are diversified and they compete 
amongst each other only with their botulinum toxin business units. 51  
Rivalry among existing competitors 
Botulinum toxin industry, both for cosmetic and therapeutic use, is assumed to be a 
fruitful one. This argument has been supported by its strong market growth. Mentor 
Corporation estimates in its Annual report for 2007, that the worldwide market for 
botulinum toxin products amounts to approximately US$ 1,4 billion, of which 
approximately 55% relates to therapeutic uses and 45% to cosmetic use. Furthermore, 
according to Morgan Stanley’s Estimation in 2006, the botulinum market will grow to 
                                                 
50 Hitt, M.,  A., Ireland, R., D., and Hoskisson, R., E. (2005) Strategic Management Competitiveness and 
Globalization, Concept and Cases, International Student Edition, 6th edition, South-Western,  Thomson 
Corporation, pg. 52  
51 Markovitz, Z.N., (1987) Hidden Sector competitor analysis, September/October Planning Review   
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about US$ 2 billion by 2010. 52 This represents a market growth of 42,86% in comparison 
to the 2007.  The growth over the coming year is expected to continue this positive trend 
due to growing consumer awareness, aging baby boomers, consumer desire to withhold a 
young appearance, consumers’ high income, social acceptance of aesthetic practices and 
by new therapeutic applications.53, 54In that manner, it is worth to mention that in the US, 
quarterly sales of botulinum pharmaceuticals have increased about 20 times compared to 
10 years ago. Furthermore, paper presentations and permits for new fields of application 
have continuously increased every 10 years.55 Below is a 10 year market growth of 
botulinum toxin market presented by Medy-tox corporation. The graph illustrates the 
growth path of botulinum toxin which was slow in the 90s but strongly increased in 
2000s.  
Figure 4. A 10 year market growth of BTX  
 
 
Source: Medy-Tox’ web site,  http://www.medy-tox.co.kr/2008_eng/04/sub05.php; 17.09.2008.   
The botulinum toxin industry is characterized by a diversity of players, some market 
reports name as much as 19 different players56. This analysis will group the 
manufacturers into two main categories: the branded manufacturers and “generic” 
manufacturers. Branded manufacturers are established produces, possessing a botulinum 
toxin branded product. After the preliminary research branded producers are found to be 
                                                 
52 Medy-Tox’ web site, http://www.medy-tox.co.kr/2008_eng/04/sub05.php; 17.11.2009.  
53 Global Biotech Forum’s web site, http://www.globalbiotechforum.org/gbf/tech_memo_file/TM_Medy-
Tox_meditoxin_.pdf ; 17.09.2008.  
54 Merz GmbH & Co, Annual report 2006/07 
55 Medy-Tox’ web site, http://www.medy-tox.co.kr/2008_eng/04/sub05.php ; last visited 17.09.2008.  
56 Report Linker’s web site, http://www.reportlinker.com/p0119494/World-Botulinum-Toxin-Market.html; 
Reuters’ web site http://www.reuters.com/article/pressRelease/idUS72672+18-May-2009+BW20090518  
18.10.2009.  
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the following companies: Allergan, Ipsen, Medy-tox, Merz Pharmaceuticals, Mentor 
Corporation and Solstice Neuroscience. “Generic” manufacturers are these that produce 
botulinum toxin but do not have established botulinum toxin branded products. These 
would include (for example Chinese, or Hong Kong) manufacturers that sell the toxin 
OTC57 through the Internet.  
The botulinum toxin market is dominated by Allergan. According to Allergan’s 10-K 
report for 2007, they owed more than 85% of the total botulinum market share in 2007. 
This categorizes Allergan as a dominant and powerful market player. 58 The second 
biggest manufacturer is Ipsen. According to the Ipsen’s registration report for 2007, they 
claim that they owed  15% of the global market in the  2007.59 According to the 
announcements from Allergan and Ipsen, the market in 2007 was divided only among the 
two of them. In 2008, Allergan possessed approximately 83% and Ipsen 13% of the 
market. The rest of the manufacturers share the remaining 4%.60 This means that the 
overall rivaling forces among BTX manufacturers are not so strong. However, the rivalry 
among the followers may be enhanced when fighting among themselves to capture the 
market share. (Table 3.)  
Table 2. Net sales of the most important players and their related market share 
    2007 2008 
Total market value** (estimated in US $ ) 1 400 000 1 568 000
Allergan's net sales (US $) 1 211 800 1 310 900
Ipsen's net sales (US $, calculated according 
the ex. rate on the 31.12.*) 205 350 201 625
rest of the market -17 150 55 475
4       
Market shares 2007 2008 
Allergan's net sales (US $) 86,6 % 83,6 %
Ipsen's net sales (US $, calculated according 
the ex. rate on the 31.12. *) 14,7 % 12,9 %
Rest of the market   3,5 %
Source: calculated by author 
* http://www.xe.com/ 
                                                 
57 OTC- over the counter= without prescription  
58 Allergan Inc., (2009) Form 10-K for 2008.  
59 Ipsen (2008) Registration document for 2007  
60 This was calculated by author according to the assumption that the BTX market will grow 12% per year. 
The 12% growth rate resulted from the fact that the market was evaluated to amounted to US$  1,4 billion 
in 2007 and should equal US$  2 billion by 2010.  By assuming the annual growth rate of approximately 12 
% the market reaches the estimated US$ 2 billion by 2010. 
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Internet supply webpages such as www.ecplaza.net or www.alibaba.com  list several 
(less then 10) “generic” suppliers of BTX. However, since they fall in the remaining 4% 
of the market share it is assumed that their power is not significant.  
Established manufacturers (Allergan  plus 5 followers) are aware of the lucrative nature 
of the botulinum toxin business and therefore maintain strong commitment to it. 
Botulinum toxin type A is one of the most important Allergan’s products whose sales 
represented approximately 30%, 31% and 33% of Allergan’s total consolidated product 
net sales in 2008, 2007 and 2006 respectively. Ipsen’s Dysport is within the four most 
selling Ipsen’s products (holds 3rd place in 2007) with its share rising from 11% in 2004 
to 14% in 2007. 61 Merz Pharmaceuticals also defined aesthetics as its future field of 
expertise. In line with that goal it will aim to position itself as a complete provider of 
non-operative aesthetics in which range the botulinum toxin falls.62 Mentor Corporation 
states that although the botulinum toxin project does not have a great share in the total net 
sales of the Mentor Corporation, it is one of their strategic projects: “The increase in 
research and development spending was primarily to support key strategic product 
development programs including … our botulinum toxin project …” 63 Mentor Corp is 
developing a next generation botulinum toxin type A product based on proprietary 
technology that yields a formulation designed to be purer than other commercially 
available botulinum toxin products.64 Medy-Tox, a biotech venture company, was 
established in 2000 with the goal of developing botulinum toxin-based injections. They 
have two main product lines of which one is Neuronox , a botulinum toxin type A. 
Taking into account its efficency, low risk, and price compared with competitive 
products, Neuronox® is continually becoming the most welcomed choice of botulinum 
toxin drug for both doctors and patients in the world. Moreover, the Bank of America 
Securities research report mentioned Medy-Tox as a leader in the botulinum market.65 
Solstice Neurosciences, Inc. is also a specialty biopharmaceutical company founded in 
2004 in the USA. Solstice’s first product, Myobloc®/NeuroBloc® Injectable Solution, 
                                                 
61 Allergan Inc., (2009) Form 10-K for 2008.  
62 Merz GmbH & Co. KGaA,  (2007)  Annual report 2006/2007 
63 Mentor Corporation, (2007) Annual report for 2006 
64 ibidum 
65 Medy-Tox Inc Technology, http://www.medy-tox.co.kr/2008_eng/01/sub02.php ; 17.09.2008.  
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represents the only botulinum toxin type B currently available to physicians and patients 
worldwide. 66  It can be concluded that all of the above manufacturers are aware of the 
botulinum toxin potential and aim at strengthening their position in that segment.  
The most differentiated product is Allergan’s Botox®. Its differentiation is so strong that 
the whole botulinum toxin industry is often named after it - botox. A price for cosmetic 
treatments with botulinum toxin differs according the amount needed to treat a certain 
area. Botox® costs between $ 500 and $ 2000 US and it is expected for a patient to pay 
this every 4-6 months.67 However, the average Botox® treatment price, is assumed to  
range from $350 to $500 for each area injected. These costs vary also according to 
geographic region and depending on the doctor who performs the procedure.68 Dysport® 
on the other hand is claimed to be cheaper, ranging from $360 to $400 depending on the 
amount of correction necessary. It is claimed that the Dysport® cost less per unit than 
Botox®. However, the disadvantage is that more Dysport® units are needed per area 
compared to Botox®.  75 Dysport® units cost approximately $300 but they equal  25 
units of Botox®. 69 Furthermore, products such as Dysport®, Purtox®, Xeomin® are 
considered to be more pure and consist fewer antigens that can lead to resistance to the 
product. 70 Price competition exists among the manufacturers but they are aiming to 
compete on other product features. These features embrace different ways of customer 
support like providing them with all necessary information (through Internet and open 
phone lines) and if needed with financial help(Allergan), assistance programs(Allergan) 
and most importantly, with better quality of the product i.e. better purity and less antigens 
(Ipsen, Merz, Mentor Corporation). The competition on other dimensions other then price 
improves customer value and if companies find the way to serve different customer 
segments this will weaken the rivalry and lead to positive sum. However, in the BTX 
market, additional benefits were imposed with the aim not only to acquire new customers 
but also to convince the opponents’ customers to switch. Hence, here the competition on 
dimensions other than price is assumed to fuel the rivalry.  
                                                 
66 Solstice Neurosciences’ web site, http://www.solsticeneuro.com/company/overview.html; 11.09.2008.  
67 Botox’ web site, http://www.botox-cosmetic-surgery.com/botox_price.htm ; 05.12.2009. 
68 DocShop web site http://www.docshop.com/education/dermatology/injectables/botox/cost/ ;  05.12.2009.  
69 RealSelf’s web site http://www.realself.com/question/how-much-does-dysport-cost; 05.12. 2009  
70 Lam Facial Plastics’ web site http://lfp-blog.com/questions/lam-facial-plastics/botox-competitors-
coming-soon-reloxin-purtox-xeomin/137/; 05.12.2009.  
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To conclude, the main forces shaping the rivalry among existing competitors are 
numerousness of competitors, industry growth, exit barriers, commitment to the industry 
business, price competition and competition on other dimensions. All of them strengthen 
the rivalry except the numerousness of competitors and industry growth. Dominance of 
the single firm  and small group of following companies, as well as affluent industry 
growth weaken the rivalry and encourage entrance.  
 
The graph below shows the forces shaping the rivalry among existing competitors. The 
graph shows whether a factor has a strong (5) or low (1) impact. Therefore, although the 
industry growth is strong, that factor weakens the rivalry and therefore is here marked as 
a weak driver (estimated to equal 1).  
 
Figure 5. Rivalry among  existing competitors 
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The power of substitutes 
Substitute solutions greatly differ for BTX use in the cosmetic and therapeutic treatments.  
Botulinum toxin used for therapeutic treatments, have few, or in some cases no 
substitutes at all. 71 For example, botulinum toxin is held to be best treatment for cervical 
dystonia72,73, as is the case for Blepharospasm (excessive blinking)74. If botulinum toxin 
treatment does not help Blepharospasm patients then surgery is an option. On the other 
hand, treating hyperhidrosis for example provides patients with two main substitutes: 
antidepressants and anxiolytics. The power of substitutes for therapeutic use is 
dependable upon substitutes that are available for that particular therapeutic problem.  
 
Use of botulinum toxin in (cosmetic) treatments has several advantages: it is a non 
surgical, low-time consuming, painfree and easy procedure. Furthermore, its effect arise 
relatively fast after the procedure, within 24-48 hours after receiving Botox®, wrinkles 
are gone and the effect can last up to 4 months75. In addition, the procedures poses little 
to no risk. The cosmetic treatment’s characteristics have therefore been difficult to beat 
by any other substitute. Alternatives to BTX cosmetic treatments that have usually been 
mentioned are: serum (injection-free alternative made from biological ingredients), 
collagen (as a substance in the anti-aging creams or as wrinkle fillers), restylane (the 
latest substitute for BTX treatment, is hyaluronic acid derivative used to produce fullness 
in the skin), snipping the muscle (a surgical process), conventional surgeries and REX 
(makes use of radiofrequency energy, which is targeted at the motor neurons to weaken 
them so that they are unable to connect to the muscle that causes frowning).76 The 
cosmetic substitutes can be grouped into following: surgical solutions, creams, new 
alternative solutions like fillers or REX. Customers will  always prefer non surgical 
                                                 
71 Schantz E.J., Johnson E.A., (1992). Properties and use of botulinum toxin and other microbial 
neurotoxins in medicine, Microbiological review, American society for Microbiology, March issue 
72 Dystonia Foundation web site, http://www.dystonia-foundation.org/pages/more_info/46.php; 
005.12.2009.  
73 Brashear A., (2009). Botulinum toxin type A in the treatment of patients with cervical dystonia, 
Biologics: Targets 6 Therapy No. 3 
74 Blepharospasm Research Foundation web site,  http://www.blepharospasm.org/med-therapy.html; 
05.12.2009.  
75 Botox’ web site,  http://www.botoxcosmetic.com/how_botox_works/injection_process.aspx; 28.10.2009.  
76 Buzzle’s web site, http://www.buzzle.com/articles/alternatives-for-botox.html; 06.12.2009   
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treatments to surgical and fast solutions to slow and long term processes like cream use. 
Therefore, fillers/ hyaluronic acid or REX can be considered as potentially the strongest 
BTX substitutes.  
Hyaluronic acid is “a viscous slippery substance that lubricates the joints, maintains the 
shape of the eyeballs, and is a key component of connective tissue.” 77 The most known 
HA brands are  Perlane®/Restylane® produced by Medici and Juvederm® by Allergan. 
There are also brands like Aquamid, Bio-Alcamid, Dermalive, Evolence, ProCytech, 
Inamed Aestetics, Radiesse and Teosyal.78  The use of hyaluronic acid as a injectable 
dermal filler is relatively new (approved by FDA in 2003) and still unknown to potential 
customers. However, according to the ASAPS, hyaluronic acid79 is the first follower of 
the botulinum toxin cosmetic treatments in the category of the nonsurgical cosmetic 
procedures and this trend has been occurring in the same pattern for past several years. 
For example in the 2007, there were more than 2,7 million BTX injection in the USA and 
more than 1,4  million hyaluronic acid procedures. The ratio is 2:1 in favor of  BTX 
however states that hyaluronic acid is aggressively treating the BTX injections.  
The Relaxed Expressions (REX) procedure is the newest substitute method for BTX 
cosmetic procedure. Its results are already visible after one hour and last for 16-18 
months. The price of the REX is  about $1500 per procedure.80 The procedure although 
new represents a sever threat to BTX since it is non toxin based, results are shown fast, 
long lasting and the price is highly competitive to the BTX treatment.  
 
BTX use cases immunologic reactions in patients. After many treatments antibodies are 
created in the body and there is an absence of reaction to the treatment. It has been shown 
that BTX-A treatments in such cases can be substituted by treatments with other 
                                                 
77 MedicineNet’s web site, http://www.medterms.com/script/main/art.asp?articlekey=25768; 18.10.2009. 
78 Linda Briggs’ web site, http://www.lindabriggs.co.uk/fillers.htm; 18.10.2009. Emedicine’s web site 
http://emedicine.medscape.com/article/1125066-overview; 10.12.2009; About’s web site, 
http://plasticsurgery.about.com/od/minimallyinvasive/a/dermal_fillers.htm 10.12.2009 
79 Hyaluronic acid is “a viscous slippery substance that lubricates the joints, maintains the shape of the 
eyeballs, and is a key component of connective tissue.” ; MedicineNet’s web site,  
http://www.medterms.com/script/main/art.asp?articlekey=25768; 18.10.2009. 
80 Youtube’s web site http://www.youtube.com/watch?v=xZtJ_9rNp3U; 07.12.2009.  
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botulinum serotypes like BTX-F or BTX-B. However, the benefits of these treatments 
have shorter (BTX-F 1 month) duration compared to the BTX-A  treatments81  
Some other toxins have been shown to produce a similar effect to BTX. These are tetanus 
toxin, saxitoxin and tetrodoxin. However, their effects and production are not still 100% 
explored. 82 However, as the applications of BTX will increase the interest for its 
substitutes will also increase. Therefore, these toxins will also present a considerable 
threat to BTX in the future.  
 
To conclude, the power of substitutes is different for cosmetic and therapeutic use. While 
in therapeutic use often there is no better alternative and hence the power of substitute is 
low, in cosmetics the power is stronger. There are substitutes that are cheap alternatives 
such as creams, or beneficial substitutes that overcome the problem of the immunologic 
reactions such as HA, REX or other toxins. The later presents the most threat to the BTX 
products. In addition, it is assumed that as more research will be done on the beneficial 
substitutes, their power will grow.  
Overall, it can be concluded that the treat of botulinum toxin substitutes is moderate with 
the tendency to become more serious in the future.   
Figure 6. The power of substitutes in cosmetic use of BTX 
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81 Brin, M.F., (1997) Botulinum toxin: Chemistry, Pharmacology, Toxicity and Immunology, Muscle & 
Nerve Supplement 6 
82 Schantz E.J., Johnson E.A., (1992). Properties and use of botulinum toxin and other microbial 
neurotoxins in medicine, Microbiological review, American society for Microbiology, March issue  
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The power of buyers 
When discussing the power of buyer a distinction should be made between buyers and 
end user. End users are customers that use botulinum toxin for cosmetic treatments to 
soften the gabellar facial lines or for therapeutic treatments to fight diseases like various 
muscle disorders or strabismus. Intermediate customers or also called buyers refer to 
doctors, hospitals or clinics. For both of these groups, the demand for botulinum toxin 
medicines is high and strong. Increased demand to preserve younger appearance, aging of 
baby boomers, as well as increased presence of the producers on the market and therefore 
increased customer awareness of the products leads to a growing demand for botulinum 
toxin as a cosmetic treatment and while decreasing buyers’ power. Medical customers 
also have a low power as their treatment usually depends on the BTX treatments for 
which there are currently few or hardly any substitutes are available. This is illustrated by 
the example of cervical dystonia mentioned previously, where botulinum toxin injections 
are considered to be the most effective treatment.83   
Increasing advertising of the BTX products in recent years has strengthened customers’ 
awareness and consequently enhanced demand. BTX products have mainly been used in 
Western countries. However, the Internet helped to spread the news about the benefits of 
BTX and the products have became known and hence desirable all over the world as well 
as in low income countries such as China, India, Russia or Brazil. The emerging markets 
are densely populated and desperate to follow the Western countries trends and therefore 
present another source of demand pressure.  
Most cosmetic customers are high income customers and the BTX products do not hold a 
great share of their budget. On the other hand, medical customers are not necessarily 
wealthy, and the procedure could hold a significant share of their budget. However, in 
most cases medical procedures are covered by insurance. Therefore, the customers are 
assumed not to be price-sensitive which decreases their power.  
The bargaining power of suppliers strongly increases in the case of adverse effects of the 
drug use (especially in the case of death). Customers’ complaints and law suits may cause 
companies to loose their goodwill and established image and lead governments to impose 
                                                 
83 Dystonia Foundation web site,  http://www.dystonia-
foundation.org/pages/cervical_dystonia_more_info/46.php; 18.10.2009.  
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even more strict regulations. These actions can significantly influence the producers’ 
market positioning and production costs as well as customers purchasing desire. One of 
the examples is a recent case in the USA, where due to the adverse effects, FDA 
announced changes to safety labeling of the botulinum toxin for the following brands; 
Botox®, Myobloc® and Dysport®.84  In addition, the negative publicity on adverse cases 
strongly influences customers’ choices and therefore increases their power.  
 
Intermediate customers are assumed to have strong power. The buyers of botulinum toxin 
are hospitals and medical practices as well as beauty clinics. These tend to have strong 
brand loyalty which enables them to withhold known practices, quality and service. 
Strong loyalty also results from influential branding campaigns targeting end users and 
customers demands. This can also partially explain why Allergan holds more than 85% of 
the market share. Strong loyalty towards a particular producer will increase a buyer’s 
negotiation leverage when considering switching. Additionally, buyers must comply with 
high levels of internal regulatory requirements, norms and certification imposed by 
central authorities when dealing with the medicines. This makes switching more difficult 
and hence more expensive. However, in some cases the government sponsors some drugs 
which makes it a powerful negotiator towards the botulinum toxin manufacturers.  
 
To conclude, the power of buyers in BTX market has been driven by several factors.  
These are negotiation leverage, price sensitivity and the power of  buyers/ intermediate 
customers. It has been presented above that negotiation leverage and price  insensitivity 
act in direction of decreasing  the power of buyers and customers while the intermediate 
customers influence the power in opposite direction. (Figure 7) 
 
 
 
 
 
 
                                                 
84 Medical News Today’s web site, http://www.medicalnewstoday.com/articles/148704.php, 18.10.2009.  
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Figure 7. The power of buyers 
0
1
2
3
4
Negotiation levarage
Price sensitivityThe power of intermediate
customers
 
The power of suppliers 
In the pharmaceutical industry usually the power of suppliers is usually high and one of 
the reasons for this is that subcontractors in USA are required by the FDA also to fulfill a 
variety of legislation. 85  Fulfilling regulative framework is both time consuming and 
expensive and therefore a source of bargaining power of a supplier. Another problem in 
the pharmaceutical industry is that the (sudden) loss of (an established) material supplier  
will cause an interruption in the manufacturing process which will then influence 
production and selling activities in a negative direction.  
However, the production of botulinum toxin differs from the above mentioned 
characteristics. In order to produce BTX, a company has to cultivate the Clostridium 
botulinum bacteria. It is the cultivation and the maintenance of C. botulinum that 
determines the quality of the toxin produced. In addition, the toxin production is highly 
sensitive to the laboratory conditions. 86 Therefore, it is not surprising that the 
manufacturers choose to produce it themselves rather then subcontracting it: “We 
ferment, purify and characterize the botulinum toxin used in our product Botox®”87.  
“The Ipsen group currently manufactures the toxin itself” 88 
                                                 
85 Allergan Inc., (2008) Form 10-K for 2007.  
86  Schantz E.J., Johnson E.A., (1992). Properties and use of botulinum toxin and other microbial 
neurotoxins in medicine, Microbiological review, American society for Microbiology, March issue 
87 Allergan Inc., (2008) Form 10-K for 2007,  pg. 14  
88 Ipsen (2008) Registration document for 2007, pg. 39  
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However, there is only one company found that manufactures and sells all seven 
serotypes of botulinum toxin: Metabiologics Inc. However, Metabiologics produces 
botulinum toxin only and exclusively for research use. This gives Metabiologics high 
power on supplying botulinum toxin for R&D activities. On the other hand, Alllergan 
secures its independence in that aspect too  by fully integrated research and development 
organization with in-house discovery programs. 89  
Since there are no real suppliers in the production of the toxin and since the companies 
conduct the (most of the) production process by themselves it can be concluded that the 
bargaining power of suppliers is low or it does not exists at all.   
 
Threats of new entrants 
The entry barriers for the botulinum toxin industry are similar to those of pharmaceutics. 
They include high R&D costs, patent costs, long periods of clinical testing and regulatory 
approvals of the drug use, access to distributional channels and huge marketing and sales 
costs.  
 
The main characteristics  of the industry are high R&D costs, patent costs, regulative 
approvals of the botulinum toxin products as a drug and clinical testing costs. A new 
entrant will have to face these costs that are immense and long lasting. Strong established 
producers such as Allergan or Ipsen, are well aware of their position  in the botulinum 
toxin pharmaceutical market. Therefore, they maintain their heavy investment into further 
BTX R&D90 in order to preserve their key positions and also to make a new entrance less 
desirable. For example, Allergan invested as much as $797,9 million in its R&D activities 
in 2008, of which a great share was spent on activities related to Botox® and it aims to 
maintain this trend in the future. 91 In addition to high R&D related entry barriers, the 
BTX manufacturing process is also technically expensive, complex and requires 
                                                 
89 Allergan Inc., (2008) Form 10-K for 2007.  
90 Mentor Corporation, (2007) Annual report for 2006 
91 Allergan Inc., (2009) Form 10-K for 2008.  
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significant lead time. 92 For example, in 2007 Ipsen invested €17,7 million for the 
facilities to produce a new packaging unit for Dysport®.93 Not only that heavy 
investment in R&D, and patenting the use of BTX are means of incumbents to impede 
discourage new entrant these factors also present high capital requirements a new entrant 
has to consume.  
Another great barrier lies in the fact that BTX products and (production) procedures are 
subject to the regulatory review and assent. BTX used in therapeutic treatments requires 
approval of medial regulatory bodies such as FDA in the USA or EMEA in the European 
Union. Cosmetic use of BTX is a subject to regulative assessment as well, but having a 
FDA approval is not a necessity. Furthermore, the manufacturing facilities are also 
controlled and evaluated. For example, a facility of Mentor Corporation is subject to 
regulation by the US Department of Health and Human Services, Centers for Disease 
Control due to the nature of the biological agent used to manufacture BTX product.94  
Failure to comply with the regulations affects the manufacturing process, delivery time, 
as well as the sales and income results of a producer and therefore increasing the power 
of this barrier. In addition, constituted access to regulative and legislative bodies makes it 
easier (due to the experience) for a producer to  challenge a new entrant’s patent 
applications on the botulinum toxin issues. For example, there has been a patent and 
competition law dispute with Merz Pharmaceuticals in 2006 concerning the Xeomin® 
and Botox®. Although a mutual agreement was reached in August 2006, disputes like 
that pose additional costs on new entrants.  
 
Current industry players have established access to and relationships with different sorts 
of distribution channels. In order to strengthen distributional channel and/or intermediate 
customers, producers have also developed training modules and seminars to update 
physicians regarding the BTX products. 95  Furthermore, they sign license agreements 
with other big pharmaceutical companies through which they gain access to new markets. 
For example, through the license to GlaxoSmithKline, Allergan entered the Japanese and 
                                                 
92 Allergan Inc., (2008) Form 10-K for 2007.  
93 Ipsen (2008) Registration document for 2007  
94 Mentor Corporation, (2007) Annual report for 2006 
95 Allergan Inc., (2008) Form 10-K for 2007.  
 35
Chinese markets. Medy-Tox  has signed a technology transfer and commercialization 
agreement with Q-Med AB and openly seeking global marketing partners in worldwide 
commercialization and development of their BTX products.96 Ipsen has license 
agreements with Aestetica and Galderma that are valid unil 2039 and enabled Ipsen to 
access the USA, Canada, Japan, the European continent, Latin America and the rest of 
the world. 97  
 
Sales and marketing cost are also ample. Not only do the current players have  well 
established relationship with distributional channels, but they also have established strong 
brands. The “leading” product on the market is Allergan’s Botox®. This product has been 
present on the market for the last 20 years and has a market share of more than 85%. This 
product has achieved such a strong image that the whole BTX industry is often named 
after it.  This has enabled it to gain customers’ affection, acceptance and finally 
satisfaction over the past two decades. Although the market has been dominated by 
Allergan, each new entrant (Ipsen, Merz, Mentor Corporation)  offered a BTX product 
(Dysport, Purtox, Xeomin) that was more pure than Botox®. Their main argument to 
acquire new or takeover customers is higher BTX purity and therefore, less side-and 
adverse-effects to the BTX treatments. More on product differentiation and competition 
on other factors than price, as well as on customers switching costs, has been mentioned 
in the rivalry among existing competitors part.  
Finally, economies of scale apply to BTX production especially regarding the  R&D and 
marketing costs.  
 
It can be concluded that there are several factors determining the threat of new entrant. 
These include economies of scale, product differentiation, capital requirements, switching 
costs, access to distributional channels, market growth, regulations, incumbent’s reaction 
to the new entry and a number of companies that hold the great stake of the market. The 
factors act in different direction. While centralization of market share around Allergan, 
moderate switching costs and market growth encourage the entrance of new players, the 
                                                 
96 Medy-Tox Inc Technology, http://www.medy-tox.co.kr/2008_eng/; last visited 02.08.2008.  
97 Ipsen (2008) Registration document for 2007  
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other determinants impede new entrances.  Graph below presents the named factors and 
how they leverage a potential of a new entrant. If a factor is influencing a new entrant 
positively it will be graded with higher grades. On the other hand, if a factor is 
discouraging new entrance it will be assigned lower grades.  
 
Figure 8.  The threat of new entrants 
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5. CONCLUSION AND RECOMMENDATIONS 
The aim of this paper was to analyze whether the BTX industry is a profitable to enter. 
Since the Porter claims that the industry is profitable if the structure of the industry is 
attractive, the Porter’s five forces model was used to determine the structure of BTX 
industry and its attractiveness. The model was used particularly because it helps to define 
different forces shaping the industry structure.  
 
In order to define how the forces influence the industry, drivers defining a particular 
force were evaluated. The evaluation of these elements is summarized in the table below 
(Table 3.).  
 
Table 3.  Evaluation of drivers shaping the Porter’s five forces of BTX industry 
 
The factor 
increases the 
force/threat/power 
if it is: 
BTX 
industry 
case 
The threat of new entrants     
Entry barriers low high 
Economies of scale high high 
Product differentiation low medium 
Capital requirements low high 
Switching costs low medium 
Access to  distribution channels easy difficult 
Market growth high high 
Government policy/Regulations low high 
Incumbents' reaction to the new entry high medium 
A number of companies that hold great stake of the 
market low low 
Bargaining power of suppliers high low 
The power of buyers     
Negotiation leverage: high low 
Price sensitivity high low 
The power of intermediate customers high high 
Threat of substitutes:     
Quality and function of a substitute high medium 
Switching costs low diverse 
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Rivalry among existing competitors:     
Numerousness of competitors high low 
Industry growth low high 
Exit barriers high high 
Commitment to the industry business high high 
Price competition: high medium 
Competition on other dimensions low medium 
 
It can be concluded that among the five forces, the rivalry among existing competitors is 
the strongest force in BTX industry. This is mainly due to the high exit barriers and high 
commitment to the industry. Price competition and competition on other dimensions is 
moderate expressed. On the other hand, rivalry is weakening by small number of market 
players and promising industry growth that should continue the path in the future. The 
threat of new entrants, threat of substitutes and the power of buyers have moderate to 
high influence. In a case of the threat of new entry, this is mainly due to the high entry 
barriers that are shaped by high capital and regulative requirements and established 
relationship to the distribution channels.  On the other hand, small number of 
manufacturers and promising market growth attract new entrants. Factors such as product 
differentiation, switching costs and incumbent’s reaction to the new entry have moderate 
influence. Incumbent’s reaction to the new entry is strongly expressed by manufacturers 
through maintenance of heavily investments in the BTX R&D. However, incumbents 
reaction to new entry is not characterized by price wars since producers are focusing 
more on penetrating the new  markets.  The tendency of strong influence of the power of 
buyers is due to the strong power of intermediate customers. The threat of substitutes is, 
on the other hand, mostly result of the emerging substitutes like REX that will gain power 
through increasing use and overcoming disadvantages of the current BTX products (side 
and adverse effects) in the future. Overall, the botulinum toxin industry is characterized 
by relatively strong rivalry, moderate threat of new entrants, moderate threat of 
substitutes, moderate power of buyers and low power of suppliers (Figure 9.).  If this 
BTX industry structure is compared to the  Porters structure of attractive industry which 
is characterized with few substitutes, modest bargaining power of suppliers and buyers, 
stable rivalry and high entry barriers it is evident that the BTX industry fulfills these 
criteria. Therefore, the BTX industry is assumed to be profitable to enter.  
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Figure 9. Porter’s five forces of botulinum toxin industry 
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However, the main threats to a new entry lie in the high capital, R&D and patent costs. 
Also, threats are hidden in the high power of intermediate customers and increased usage 
of substitutes that overcome BTX disadvantages. Furthermore, although the suppliers 
have low bargaining power, a new entrant should be aware that this is due to the 
particularity of the BTX production process and hence the complex manufacturing plays 
a vital role for the industry profitability and hence should not be underestimated.  
On the other hand, industry growth and few market players present opportunity for an 
entrant. A strength of the industry is that a high growth causes firms to concentrate more 
on penetrating new markets and customers instead of stealing customers from each other. 
Less price wars are assumed to take place as well. This is also supported by the fact that 
the industry is dominant by one producer which decreases the rivalry forces and also 
price competition. Furthermore, relative differentiation of the products and competition 
on the other dimension rather price can be source of positioning for a new entrant. The 
new entrant should seek to find the niche place among existing payers where it satisfies 
the needs that are not fully satisfied for example; to offer a product that has causes no 
immunologic reactions. Hence is could position itself as a producer offering a premium 
product that can be used over and over. Moreover, an entrant should take the advantage 
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of emerging markets. Existing players have been focusing their offers to the developing 
countries mostly since they have higher income and hence better purchasing power. 
However, the opportunity lies also in emerging markets like China or Brazil whose 
income is rising and hence will be more willing to purchase products that enhance quality 
of life like do BTX products. This is to be accompanied with the fact that the BTX 
cosmetic treatments are usually so demanded that customers do not wait for regulative 
approvals to be put into the power (which greatly decreases the entry costs).   
 
To conclude, it has been shown that there are promising opportunities for a new entrant in 
the BTX market despite high entry barriers. In addition, future studies are encouraged to 
be done to analyze the appropriate market entry strategies particular to this industry.   
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Limitations   
There are some limitations of the case study research method used, as well as in the use 
of the document analysis data collection method. They include construct validity, 
personal integrity, prejudices and personal biases that may affect how the research has 
been conducted or which research methods were used. In addition, misinterpretation of 
written information may arise when conducting a document analysis. Desk research data 
collection includes limitations such as outdated or incorrect results and the amount of 
information available may be very limited. Subjective analysis used to illustrate the 
Porter’s five forces elements is limited by author’s personal and subjective interpretation.  
   
Furthermore, companies are not eager to release their strategies. Thus analyzing them is 
difficult. Companies reveal only as much information as is required from them to publish 
or as much as they find it strategically beneficial. Hence, it has been difficult to obtain 
data that can potentially be of importance for the analysis. Therefore, the biggest 
limitation lies in the fact that the analysis has been performed only on the information 
publicly available and collected from secondary data.  
 
Finally, limitations may result from the fact that the author of the topic had little prior-
thesis knowledge of the botulinum toxin industry and therefore cannot guarantee that all 
of the analyses provided constitute a complete or correct picture of all forces shaping and 
influencing the industry. 
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